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ABSTRACT
Squamous cell carcinoma of the anorectal canal (SCCA) is a rare HPV-related
malignancy that is steadily increasing in incidence. A high unmet need exists for
patients with persistent loco-regional and metastatic disease. Axalimogene filolisbac
(ADXS11-001) is an investigational immunotherapy that stimulates tumor-specific
responses against HPV-associated cancers, and has demonstrated benefit in
metastatic cervical cancer. We conducted this single-arm, multicenter, phase 2 trial
in patients with persistent/recurrent, loco-regional or metastatic SCCA. Patients
received ADXS11-001, 1 × 109 colony-forming units intravenously every 3 weeks.
A Simon 2-stage design was used to test primary co-endpoints of overall response
rate (ORR) and 6-month progression-free survival (PFS) rate. Study would proceed
to full enrollment if ORR ≥ 10% or 6-month PFS rate ≥ 20%. Thirty-six patients were
treated; 29 patients were evaluable for response. One patient had a prolonged partial
response (3.4% ORR). The 6-month PFS rate was 15.5%. Grade 3 adverse event
were noted in 10 patients, with the majority being cytokine-release symptoms; one
grade 4 adverse event was noted. No grade 5 adverse events occurred. ADXS11-001
was safe and well-tolerated in patients with SCCA. However, this study did not meet
either primary endpoint. ADXS11-001 may be more beneficial when administered in
combination with other cytotoxic or targeted agents.

INTRODUCTION

common histology (85%), followed by adenocarcinoma
(10%) [3]. Most patients with localized SCCA (stage
I-III) can be cured by chemoradiation [4, 5], however up
to 25% of patients develop distant metastases (Stage IV
disease) [6, 7]. Patients with Stage IV disease have dismal
prognoses, with 5-year survival rates of 15–20% [8].
Limited prospective trials have been completed in
patients with metastatic disease due to the rarity of the
disease. A single arm phase II trial of docetaxel, cisplatin,
and 5-fluoruracil (5-FU) in treatment naïve patients
resulted an impressive response rate of 89% [9]. A small

It is estimated that approximately 8600 new cases of
anal cancer will be diagnosed in the United States in 2019,
and 1160 people will die from the disease [1, 2]. Although
accounting for less than 1% of all malignancies, anal
cancer has been increasing in incidence by 2.2% per year
for the past decade, while annual death rates increased by
2.9% per year from 2005 to 2014 [1]. Primary tumors of
the anal canal can be of multiple types, with squamous cell
carcinoma of the anal canal (SCCA) comprising the most
www.oncotarget.com
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randomized phase II trial compared 5-FU plus cisplatin
vs. carboplatin plus paclitaxel noting equivalent response
rates of 57% vs. 59%, respectively [10].
The most common risk factor for anal cancer is
infection with human papilloma virus (HPV), which is
found in more than 90% of anal cancer cases [11–14]. The
HPV proteins E6 and E7 play central roles in transforming
anal squamous epithelium into invasive cancer [15–17],
are immunogenic, and may trigger an anti-tumor immune
response by recruitment of tumor-infiltrating lymphocytes
[18, 19]. Given the immunogenicity associated with these
tumors, a recent single-arm phase II study of patients
with previously-treated metastatic SCCA examined the
response rate and safety of nivolumab, an anti-PD-1
antibody that boosts antitumor immunity by diminishing
immune checkpoint activity [20]. Among 37 patients, the
overall response rate (ORR) was 24% [95% confidence
interval [CI]: 15%–33%]) with an observed prolonged
complete response (CR) in one patient longer than 2
years. The median progression-free survival (PFS) was
4.1 months (95% CI 3.0–7.9 months) and 6-month PFS
was 38% (95% CI: 24%–60%). A Phase IB study with
pembrolizumab found similar benefit in patients with
PD-L1 overexpressing unresectable anal cancer, with an
ORR of 17% [95% CI: 5%–37%] and median PFS of 3.0
months [95% CI: 1.7–7.3 months]) [21]. Based on these
promising results, nivolumab and pembrolizumab are
currently recommended as treatment options in previously
treated patients with metastatic anal cancer [22]. While
these two encouraging studies illustrate the potential
benefits of immunotherapy in patients with recurrent or
metastatic anal cancer there is still a need for additional
therapies to treat this orphan disease.
Axalimogene filolisbac (ADXS11-001) is a new
immunotherapeutic agent for HPV-associated locally
advanced cancers [23, 24]. This novel agent consists
of a live, irreversibly-attenuated (prfA-deficient), and
nonpathogenic strain of the intracellular bacterium Listeria
monocytogenes (Lm), which has been bioengineered
to secrete an antigen-adjuvant fusion protein between
Listeriolysin O (LLO) and the HPV-16 E7 oncoprotein [23,
24]. Preclinical studies found that ADXS11-001 stimulated
tumor-specific responses against HPV-associated cancers
by stimulating the innate, adaptive and humoral arms
of the immune system. Furthermore, treatment reduced
immune tolerance by neutralizing regulatory T-cells
and myeloid-derived suppressor cells within the tumor
microenvironment [25–34]. In a single institution pilot
study, ADXS11-001 was evaluated in combination with
radiation and chemotherapy in locally advanced highrisk anal cancer (T>4 cm and/or lymphadenopathy). All
9 assessable patients had complete clinical responses
of the primary tumor at six months. Eight of 9 patients
(89%) were progression-free after a median follow-up of
42 months [35]. ADXS11-001 has also shown clinically
meaningful responses in patients with recurrent metastatic
www.oncotarget.com

cervical cancer and is being evaluated in an ongoing phase
III clinical trial, NCT02853604 [36, 37]. We report here
the first-in-human study to assess tumor response and
safety of ADXS11-001 in patients with previously treated
advanced SCCA.

RESULTS
Thirty-nine patients were screened from May 2016
to December 2016; three patients were screen failures.
Data cut-off date was August 15, 2017. Thirty-six patients
were evaluable for the safety analysis; 29 patients were
evaluable for response based on diagnostic imaging. Seven
patients withdrew from the study prior to receiving cycle 2
of therapy; 5 patients had clinical progression (3 patients
within one week of initiating therapy); 1 patient developed
a grade 3 treatment related infusion reaction; and 1 patient
was lost to follow-up. Baseline demographic data are
listed in Table 1. Prior treatment included chemotherapy
in 34 patients (94.4%) and chemoradiation in 26 patients
(72.2%) (Table 1). The median follow-up time for all
patients was 8.1 (range 1.3 to 17.9) months. Patients were
treated for a median of 9 weeks (one treatment cycle:
range 1–6) and received a median of 3 doses of ADXS-11001 (range 1–21, interquartile range 3–5). At the time of
the data cut-off, 36 patients had discontinued treatment by
meeting a protocol-specified criterion: 27 patients (75%)
due to disease progression, 2 patients (5.6%) withdrew
consent, investigator withdrew 2 patients (5.6%), and 4
patients (11.1%) discontinued due to an adverse event
(Figure 1). Treatment remains ongoing for 1 patient as of
February 16, 2018.
In Stage I of the study, 1 patient achieved a partial
response (PR; ORR 3.4%; Table 2) with a duration of
6.0 months, and a maximum decrease in size of target
lesions by 83%. Six patients had stable disease (SD;
20.7%) with all of these patients meeting the definition
of disease control by maintaining response for at least 24
weeks. Twenty patients (55.6%) had disease progression
at initial restaging. The 6-month PFS was 15.5% (95% CI
5.7–29.6%). The median PFS (Figure 2) was 2.0 months
(95% CI 1.8–2.1 mos.) with a median OS (Figure 3) of
12.6 mos. (95% CI 5.4–Not Estimable).

Toxicities
Of the 36 patients treated with ADXS11-001, the
most common treatment-related adverse events occurring
in ≥ 25% of patients were chills, pyrexia, nausea,
hypotension, vomiting, fatigue, and headache (Table 3).
Grade 3 treatment-related adverse events occurred in
10 patients (27.8%); 1 patient each had cytokine release
syndrome, ascites, diarrhea, encephalopathy, and acute
renal failure; two patients each had an infusion-related
reaction, dyspnea, and increased hepatic enzymes; and 4
patients had hypotension. One patient (2.8%) had a Grade
1335
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Table 1: Demographics and baseline characteristics
All Treated (n = 36)
Median age, years (range)
Female gender, n (%)
Race, n (%)
Asian
Black or African American
White
American Indian or Alaskan Native
ECOG performance status, n (%)
0
1
Time from initial diagnosis to first dose (N = 28)
Median time, months (range)
Tumor stage at entry, n (%)
II
IIA
IIB
III
IIIA
IIIB
IV
Other
Prior cancer surgery, n (%)
Yes
No
Prior therapy, n (%)
Any
Chemotherapy
Immunotherapy
Number of prior regimens, n (%)
1
2
3
≥4
ECOG, Eastern Cooperative Oncology Group.

60.5 (43, 77)
29 (80.6)
2 (5.6)
1 (2.8)
32 (88.9)
1 (2.8)
25 (69.4)
11 (30.6)
29.7 (9, 201)
1 (2.8)
0
1 (2.8)
2 (5.6)
0
0
29 (80.6)
3 (8.3)
22 (61.1)
14 (38.9)
35 (97.2)
34 (94.4)
10 (27.8)
2 (5.6)
6 (16.7)
7 (19.4)
20 (55.6)

4 treatment-related adverse events of respiratory failure.
(Table 3). There were no treatment-related deaths (Table 3).
Five patients discontinued the study because of drugrelated toxicity. There were no cases of delayed listeria
infection during the Lm surveillance monitoring period.

treatment for refractory metastatic SCCA. There are a
limited number of treatment options available for this
population. Historically, doublet chemotherapy with
cisplatin and fluorouracil was recognized as the most
common treatment provided for treatment naïve patients.
The previously conducted studies of immune checkpoint
inhibitors in this population demonstrated findings which
are encouraging with respect to providing meaningful
clinical benefit for these patients [40]. However, the need
for novel treatments still remains.

DISCUSSION
This study was prospectively designed to evaluate
ADXS11-001 in patients who had received previous
www.oncotarget.com
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Table 2: Response
Efficacy-Evaluable Populationa
(n = 29)
Response, n (%)b
CR
0 (0)
PR
1 (3.4)
SD
6 (20.7)
PD
20 (69.0)
NE
2 (6.9)
c
ORR, % (95% CI)
3.4 (0, 17.8)
d
DCR, % (95% CI)
24.1 (10.3, 24.5)
Median PFS, months (95% CI)
2.0 (1.8, 2.1)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate.
PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
a
All enrolled patients who had at least one post-baseline tumor assessment.
b
Best overall responses were identical with or without response confirmation.
c
ORR = (CR + PR)/total × 100.
d
DCR = (CR + PR + SD)/total × 100.
Although our multicenter phase II study, did not
fulfill the primary endpoint of greater than 20% PFS, there
are advantages to this clinical analysis. This is the first,
multicenter trial of a novel bioengineered vaccine that
we are aware of specific to HPV16/E7. Furthermore, a
durable PR was achieved in a patient who had previously

failed immune checkpoint inhibitor inhibition. In addition,
ADXS11-001 was well-tolerated with a safety profile
consistent with what has been reported in other HPVassociated malignancies [24]. The median OS, measured
from the time of the first treatment, was 12.6 months.
This result was comparable to that seen in the nivolumab

Figure 1: Consort flow diagram. aSafety population: all patients who received at least one dose of ADXS11-001 (note: all 36 enrolled

patients received at least one dose). bEfficacy population: all patients who received at least one dose of ADXS11-011 and had at least one
post-baseline tumor response assessment. Note: 31 patients were planned for Stage 1 but patients consented at the time of the 31st patient
were allowed to enroll, leading to 5 additional patients.
www.oncotarget.com
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Table 3: Safety
Safety Population (n = 36)
Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Total

Chills

1 (2.8)

21 (58.3)

0

0

0

22 (61.1)

Pyrexia

9 (25.0)

9 (25.0)

0

0

0

18 (50.0)

Nausea

13 (36.1)

4 (11.1)

0

0

0

17 (47.2)

0

12 (33.3)

4 (11.1)

0

0

16 (44.4)

Vomiting

10 (27.8)

3 (8.3)

0

0

0

13 (36.1)

Fatigue

8 (22.2)

4 (11.1)

0

0

0

12 (33.3)

Headache

7 (19.4)

4 (11.1)

0

0

0

11 (30.6)

0

6 (16.7)

2 (5.6)

0

0

8 (22.2)

Back pain

4 (11.1)

4 (11.1)

0

0

0

8 (22.2)

Diarrhea

2 (5.6)

2 (5.6)

1 (2.8)

0

0

5 (13.9)

Abdominal distension

1 (2.8)

2 (5.6)

0

0

0

3 (8.3)

0

2 (5.6)

1 (2.8)

0

0

3 (8.3)

Decreased appetite

2 (5.6)

1 (2.8)

0

0

0

3 (8.3)

Dizziness

1 (2.8)

2 (5.6)

0

0

0

3 (8.3)

Dyspnea

1 (2.8)

0

2 (5.6)

0

0

3 (8.3)

Total Adverse Events

0

2 (5.6)

8 (22.2)

1 (2.8)

0

11 (30.6)

Diarrhea

0

1 (2.8)

1 (2.8)

0

0

2 (5.6)

Hypotension

0

0

2 (5.6)

0

0

2 (5.6)

Ascites

0

0

1 (2.8)

0

0

1 (2.8)

Cytokine-release syndrome

0

0

1 (2.8)

0

0

1 (2.8)

Pneumonia

0

1 (2.8)

0

0

0

1 (2.8)

Infusion-related reaction

0

0

1 (2.8)

0

0

1 (2.8)

Encephalopathy

0

0

1 (2.8)

0

0

1 (2.8)

Acute kidney injury

0

0

1 (2.8)

0

0

1 (2.8)

Respiratory failure

0

0

0

1 (2.8)

0

1 (2.8)

Treatment-related Adverse Events, n (%)

Hypotension

Infusion-related reaction

Cytokine-release syndrome

Serious treatment-related Adverse Events, n (%)

WBC, white blood cell. Shown are treatment-related adverse events by worst grade reported in 3 or more patients and serious treatment-related adverse
events by worst grade. Data are based on the entire safety population (n = 36).

study, with a median OS of 11.5 months (95% CI 7.1–not
estimable) [40]. It is likely that ADXS11-001 would likely
work better in combination with other treatments, such as
immune checkpoint blockade agents given their promising
single agent results in this patient population [20, 21], but
future clinical studies are needed for confirmation.
There were several limitations in this study.
This was a small single arm phase II study of which 5
patients had very early evidence of clinical progression
and were unevaluable by diagnostic imaging. Second,
due to financial constraints tissue and blood correlatives
were not collected, which did not allow characterization
of ADXS11-001’s ability to activate the innate adaptive
CD4-positive and CD8-positive T cells within the tumor,
as well as look at an association between treatment
responses for ‘responders’ and ‘non-responders’. Profiling
and quantifying immune-related gene expression in their
peripheral blood mononuclear cells (PBMCs) before and
after ADXS11-001 treatment would have been helpful
to determine whether any gene expression profiles were
www.oncotarget.com

associated with disease control. In addition, evaluating
changes in the peripheral T-cell repertoire of these
patients would have helped to determine any association
with clinical activity. Unfortunately, immunosuppressed
patients were considered to be ineligible to receive
ADXS11-001 since it is a live vaccine.
In conclusion, ADXS11-001 was safe and welltolerated. Although the primary outcome was not reached,
ADXS11-001 may benefit from further evaluation in
combination for enhanced efficacy of therapy.

MATERIALS AND METHODS
Participants
Eligible patients were at least 18 years of age and
had confirmed histopathologic diagnosis of squamous
cell cancer of the anorectal canal that was not amenable
to curative surgery. Patients must have: measurable
disease according to Response Evaluation Criteria in
1338
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Solid Tumors, Version 1.1 (RECIST v1.1) [38]; Eastern
Cooperative Oncology Group performance status of 0 or
1; adequate hematologic, hepatic and renal function; and at
least one prior line of therapy for metastatic/unresectable
disease. Patients were considered ineligible if they had:
central nervous system metastases and/or leptomeningeal
disease; a history of listeriosis or prior ADXS11-001
therapy; HIV-positive; and a history of autoimmune
disease requiring steroids or immunosuppressive agents.
Patients were ineligible if they had: undergone major
surgery within 6 weeks; received systemic steroid therapy
and/or immunosuppressive therapy for less than 7 days or
a live vaccine within 30 days. Patients with a history of

a second malignancy (excluding basal cell or squamous
cell carcinoma of the skin, or ductal carcinoma in situ of
the breast) within 2 years were also ineligible. Implanted
medical devices (e.g., orthopedic metal based plates) were
not allowed due to presumed risk for Listeria colonization.

Study design
This was a Simon two-stage, phase II, open-label,
multicenter study (NCT02399813). The overall goals of the
study were to evaluate the efficacy and safety of ADXS11001 in patients with persistent/recurrent, loco-regional or
metastatic SCCA not amenable to curative surgery.

Figure 2: Radiologic progression-free survival in the Efficacy-Evaluable population.

Figure 3: Overall survival in all treated subjects.
www.oncotarget.com
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The study was conducted at 8 centers in the United
States. The study was compliant with International
Conference on Harmonization Good Clinical Practice
guidelines for conducting, recording and reporting
clinical studies [39]. The informed consent form, protocol
and amendments were submitted and approved by the
institutional review board or independent ethics committee
for each respective investigative site.

1 × 109 CFU for up to 2 years or until a discontinuation
criterion is met. A treatment cycle is defined as 9 weeks.
Tumor assessments occurred every 9 weeks.
Patients were followed for survival via a phone
call every 3 months following ADXS11-001 treatment
discontinuation. The end of the study was to be defined as
1 year after the last patient had been enrolled.

Stage 1

Outcomes

During Stage 1, eligible patients received
intravenous doses of ADXS11-001 (Advaxis, Inc.,
Princeton, NJ, USA) at a dose of 1 × 109 colony-forming
units (CFU) every 3 weeks (i.e., day 1, 22, and 43) of a
9-week treatment cycle. Treatment continued for up to 2
years, until documented disease progression or intolerable
side effects. Response was evaluated per RECIST v1.1
[38] and immune-related RECIST (irRECIST) [40] at
baseline and every 9 weeks thereafter, based on computed
tomography and/or magnetic resonance imaging results.
To assess safety, patients were monitored for adverse
events as per the National Cancer Institute Common
Toxicity Terminology Criteria for Adverse Events (NCI
CTCAE v4.03) [41].
The study protocol mandated a total enrollment
of 31 evaluable patients into Stage 1, where evaluability
was defined as having at least 1 post-baseline response
assessment. After 31 evaluable patients had been enrolled,
further accrual was to be temporarily halted to complete
an interim efficacy analysis.

The primary efficacy co-endpoints for the study
were ORR measured by RECIST v1.1 and 6-month PFS
rate. Secondary efficacy objectives were the duration of
response, median PFS and overall survival (OS). The
primary safety endpoint was to characterize the safety
and tolerability of ADXS11-001 using NCI CTCAE v4.0
criteria.

Statistical analyses
The study employed a 2-stage design for testing the
two primary efficacy measures. The study used Simon’s
method with null and alternative hypotheses Ho: p ≤ .10
and Ha: p > .25, whereby p represents the ORR with
ADXS11-001, and determined that 31 patients needed to
be enrolled in Stage 1 and an additional 24 patients be
enrolled in Stage 2 (if 3 or more responses were observed
in Stage 1). A 2-endpoint, 2-stage decisional framework
was designed using the Two-Stage approach proposed by
Benny Zee, et al. [42]: if Stage 1 demonstrates an ORR
>10% or 6-month PFS > 20%, then enrollment will move
to Stage 2. Using the Multinomial Two-Stage approach
proposed by Benny Zee, et al. [42], we simulated 50,000
trials to examine the Type I and II errors under this design
assumption. The following estimates, including Type I
and II errors, from these simulations are: Type I error of
0.01876 with a probability of stopping early = 0.99; Type
II power is 0.9277 (See Supplementary Material for more
detail).
The analysis of the Stage 1 ORR and 6-month PFS
data was performed on the ORR evaluable population in
accordance with the protocol-defined requirements to
determine if either criterion were met to proceed with Stage
2 enrollment. All primary and secondary analyses were
also performed with the all enrolled patients. The degree
of radiographic response was determined by the treating
investigator. The primary assessment for the interim
analysis was based on confirmed radiographic responses
of CR and PR requiring confirmation with a subsequent
diagnostic imaging study 4–8 weeks later. The 95% CIs
around proportions were calculated using an exact binomial
calculation. Kaplan-Meier estimates were generated in
terms of the median PFS and survival probability at selected
time points (e.g., 2, 4, 6 and 8 months), along with the
corresponding 2-sided 95% CIs for the estimates. CIs for
median OS were based upon the methods of Brookmeyer

Stage 2
If the efficacy results from Stage 1 indicated a
response rate greater than or equal to 10% (by either
RECIST v1.1 or irRECIST) or a 6-month PFS rate greater
than or equal to 20% was observed, an additional 24
patients were to be enrolled for a total of 55 patients.

Treatment
At least 30 minutes prior to each ADXS11-001
infusion, patients completed a prophylactic regimen to
mitigate and manage potential cytokine release symptoms
consistent with the mechanism of action of ADXS11-001.
The regimen consisted of nonsteroidal anti-inflammatory
drugs (NSAIDs), antihistamines, anti-emetics, and
H2 receptor antagonists. Additional doses of NSAIDs
or antiemetics were provided on days 1–2 following
infusion, if needed. Furthermore, all patients received
a 7-day course of antibiotic therapy (oral trimethoprim/
sulfamethoxazole or ampicillin for patients with a sulfa
allergy) starting 72 hours after drug administration to help
ensure clearance of the attenuated Lm vector. In addition, a
3-year Lm surveillance period including a 6-month course
of antibiotics following treatment discontinuation.
Patients were treated with intravenous ADXS11-001
administered over 60 minutes every 3 weeks at a dose of
www.oncotarget.com
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FUNDING

and Crowley [43]. CIs for survivorship estimates were
calculated using the Greenwood formula. Disease Control
Rate (DCR) was summarized descriptively, where DCR
was defined as the proportion of patients with objective
evidence of CR, PR or SD.
All adverse events and serious adverse events were
summarized for the treatment period and for the 30-day posttreatment period. Adverse events and serious adverse events
considered related to study treatment were summarized by
frequency using descriptive statistics. All data summaries
and listings were performed using SAS Version 9.2 under
the Microsoft Windows operating system.

The study has been supported by Advaxis
Immunotherapies™.
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